These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24764283)

  • 1. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
    Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
    JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
    Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
    Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
    Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
    Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
    Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
    Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
    Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
    Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone use and risk of bladder cancer: population based cohort study.
    Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
    BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
    Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone and bladder cancer: a propensity score matched cohort study.
    Wei L; MacDonald TM; Mackenzie IS
    Br J Clin Pharmacol; 2013 Jan; 75(1):254-9. PubMed ID: 22574756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational follow-up of the PROactive study: a 6-year update.
    Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
    Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
    Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone use and the risk of bladder cancer.
    Kuo HW; Tiao MM; Ho SC; Yang CY
    Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
    Li Z; Sun M; Wang F; Shi J; Wang K
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):210-219. PubMed ID: 28025963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
    Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
    Vallarino C; Perez A; Fusco G; Liang H; Bron M; Manne S; Joseph G; Yu S
    Clin Drug Investig; 2013 Sep; 33(9):621-31. PubMed ID: 23881565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.